logo

TRAW

Traws Pharma·NASDAQ
--
--(--)
--
--(--)
3.60 / 10
Netural

Capital flows register a strong 7.19/10, driven by positive medium-trend inflows (0.528), but larger block trends remain negative, hinting at institutional hesitation. Analyst sentiment is overwhelmingly bullish (Strong Buy at 100%), yet historical performance data is limited to a single prediction with a -41.71% average return and zero win rate, undermining conviction. Together, the data imply that while retail money is flowing in, professional validation is lacking, warranting caution.

FundamentalSentiment(3.6)Technical
Fund Flow Rating
Analyst RatingStrong Buy

Wall Street Opinions

Strong Buy

Strong Buy

100%

Buy

0%

Hold

0%

Sell

0%

Strong Sell

0%

Date2025-12-03
InstitutionHC Wainwright & Co.
Times predicted1
Historical Win Rate0.0%
Is money flowing into or out of TRAW?
  • TRAW holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.60/10 (Netural).